Study of Durvalumab in Combination with Platinum and Etoposide for the First Line Treatment of Patients with Extensive-stage Small Cell Lung Cancer

Trial Identifier: D419QC00007
Sponsor: AstraZeneca
Start Date: November 2021
Primary Completion Date: June 2023
Study Completion Date: January 2025

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version
Bulgarian Translation
Czech Translation
German Translation
Italian Translation
Turkish Translation

Trial Locations

Country Location
BG Panagyurishte, BG, 4500
BG Ruse, BG, 7002
BG Sofia, BG, 1407
BG Sofia, BG, 1330
BG Sofia, BG, 1303
CA, QC Montreal, QC, CA, H4A 3J1
CZ Burgas, CZ, 180 81
CZ Olomouc, CZ, 779 00
CZ Ostrava, CZ, 703 00
DE Berlin, DE, 13125
DE Berlin, DE, 12351
DE Gauting, DE, 82131
DE Hamburg, DE, 20251
DE Jena, DE, 07747
DE Kassel, DE, 34125
DE Köln, DE, 51109
IT Ancona, IT, 60126
IT Bari, IT, 70124
IT Milano, IT, 20141
IT Napoli, IT, 80131
IT Orbassano, IT, 10043
IT Palermo, IT, 90146
IT Roma, IT, 00168
TR Adapazari, TR, 54290
TR Ankara, TR, 06010
TR Ankara, TR, 06100
TR Ankara, TR, 06800
TR Antalya, TR, 07070
TR Bursa, TR, 16059
TR Edirne, TR, 22030
TR Istanbul, TR, 34098
TR Istanbul, TR, 34722
TR Izmir, TR, 35100
TR Malatya, TR, 44280
TR Pamukkale, TR, 20070